HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial.

Video: HIV Activist Raises Hope and Warnings in New Attachment Inhibitor Trial. Leading HIV activist Nelson Vergel raises hopes but also warns HIV salvage patients and their physicians about functional monotherapy risks in the Bristol-Meyers Squibb (BMS) new attachment inhibitor study (Fostemsavir, BMS-663068) currently enrolling (2015-2016). This innovative drug, along with Taimed's
Source: Nelson Vergel's HIV Blog - Category: Infectious Diseases Authors: Source Type: blogs
More News: Blogging | Study | Warnings